NRx Pharmaceuticals Operating Expenses 2018-2024 | NRXP

NRx Pharmaceuticals operating expenses from 2018 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

NRx Pharmaceuticals Operating Expenses 2018-2024 | NRXP

NRx Pharmaceuticals operating expenses from 2018 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$78.6B
Takeda Pharmaceutical (TAK)$44.1B
Merck (MKKGY)$21.2B
Astellas Pharma (ALPMY)$20.4B
Sandoz Group AG (SDZNY)$19.7B
United Therapeutics (UTHR)$18B
Summit Therapeutics (SMMT)$15.6B
Neurocrine Biosciences (NBIX)$12.6B
Shionogi (SGIOY)$12.5B
Catalent (CTLT)$10.9B
Madrigal Pharmaceuticals (MDGL)$7.7B
Jazz Pharmaceuticals (JAZZ)$7.4B
Orion OYJ (ORINY)$6.8B
Ionis Pharmaceuticals (IONS)$6.1B
Corcept Therapeutics (CORT)$5.7B
Crinetics Pharmaceuticals (CRNX)$4.8B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.7B
Soleno Therapeutics (SLNO)$2.5B
NewAmsterdam Pharma (NAMS)$2B
Recursion Pharmaceuticals (RXRX)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.8B
Ocular Therapeutix (OCUL)$1.7B
Xencor (XNCR)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
ARS Pharmaceuticals (SPRY)$1.6B